Online first
Research paper (original)
Published online: 2024-05-20

open access

Page views 57
Article views/downloads 32
Get Citation

Connect on Social Media

Connect on Social Media

Predicting of overall survival in non-small cell lung cancer patients receiving concurrent radiochemotherapy and adjuvant durvalumab – a Polish real-world single-center experience

Barbara A. Łochowska1, Konrad Stawiski23, Kasper Kuna3, Zuzanna Nowicka3, Mariusz Lochowski4, Jacek Fijuth2

Abstract

Introduction. Adjuvant durvalumab has become a standard treatment protocol for patients with locally advanced non-small cell lung cancer (LA-NSCLC). However, there is still limited knowledge about prognostic factors in the real-world setting in this specific patient group.

Materials and methods. In our single-center retrospective study, we evaluated 45 patients to identify predictors of overall survival (OS) in LA-NSCLC. We utilized the univariable Cox proportional hazards models and we developed multivariable Cox models after adjusting for the known clinical predictors.

Results. In univariable analysis nodal status, percentage of basophils in peripheral blood before treatment and D-dimers were associated with OS. Multivariable analysis, adjusted for age, sex T characteristics, and nodal status, revealed that the percentage of basophils is a significant predictor of OS. A higher percentage of basophils was associated with improved OS (HR = 0.077, 95% CI: 0.007–0.853, p = 0.037).

Conclusions. Our study indicates that a lower serum percentage of basophils may be associated with better OS in patients with LA-NSCLC. These findings should be validated in larger cohorts.

Article available in PDF format

View PDF Download PDF file



Nowotwory. Journal of Oncology